In this review, we focus on the role of GLP-1 (and GLP-1-RAs) in the physiology of the gut-renal axis, the renoprotective mechanisms of this incretin therapies and the renal outcomes obtained in the most recognized clinical studies using GLP1-RAs in patients with T2D. Here, GLP1R is linked to type 2 diabetes mellitus.